HONG KONG – South Korea’s Celltrion Inc. (KOSDAQ:068270) successfully added another biosimilar to its portfolio, giving breast cancer patients there a cheaper alternative and securing the company’s leading position in the biosimilar monoclonal antibody (MAb) market.